Literature DB >> 10403611

Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries.

T Okamura1, K Ayajiki, H Fujioka, N Toda.   

Abstract

OBJECTIVE: The present study was undertaken to examine whether arginine vasopressin (AVP) relaxes primate coronary artery and to analyse the mechanisms of its action in reference to endothelial nitric oxide and AVP receptor subtype.
METHODS: Isometrical tension responses to AVP and desmopressin were recorded in isolated monkey coronary arteries.
RESULTS: AVP (10(-9) to 10(-7) mol/l) induced a concentration-related relaxation; endothelium-denudation abolished the response. Treatment with N(G)-nitro-L-arginine, but not the D-enantiomer, abolished the endothelium-dependent relaxation, which was restored by L-arginine. Treatment with SR49059 and [Pmp1,Tyr(Me)2]-Arg8-vasopressin, selective inhibitors of V1 receptor subtype, attenuated the relaxant response to AVP, whereas the relaxation induced by sodium nitroprusside was not affected by SR49059. Desmopressin, a V2 receptor agonist, up to 10(-8) mol/l did not elicit relaxation.
CONCLUSIONS: It is concluded that AVP-induced monkey coronary arterial relaxation is mediated via nitric oxide synthesized from L-arginine in association with stimulation of V1 receptor subtypes in the endothelium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403611     DOI: 10.1097/00004872-199917050-00011

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  17 in total

1.  Comparison of the effects of vasopressin and norepinephrine on organ perfusion during septic shock in streptozotocin-induced diabetic rats.

Authors:  Hiroshi Hinohara; Yuji Kadoi; Aya Tokue; Shigeru Saito; Chikara Kawauchi; Akio Mizutani
Journal:  J Anesth       Date:  2010-08       Impact factor: 2.078

2.  The cellular mechanisms underlying the inhibitory effects of isoflurane and sevoflurane on arginine vasopressin-induced vasoconstriction.

Authors:  Manabu Shimogai; Koji Ogawa; Yasuyuki Tokinaga; Akinori Yamazaki; Yoshio Hatano
Journal:  J Anesth       Date:  2010-10-17       Impact factor: 2.078

3.  Concurrent Use of Calcium Chloride and Arginine Vasopressin Infusions in Pediatric Patients with Acute Cardiocirculatory Failure.

Authors:  Karan B Karki; Jeffrey A Towbin; Camden Harrell; James Tansey; Joseph Krebs; William Bigelow; Arun Saini; Sachin D Tadphale
Journal:  Pediatr Cardiol       Date:  2019-05-07       Impact factor: 1.655

Review 4.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Use of vasopressin in neonatal hypertrophic obstructive cardiomyopathy: case series.

Authors:  Stephanie M Boyd; Kristin L Riley; Regan E Giesinger; Patrick J McNamara
Journal:  J Perinatol       Date:  2020-09-19       Impact factor: 2.521

6.  Vasopressin as an adjunct therapy for pulmonary hypertension: a case report.

Authors:  Andra Malikiwi; Arun Sasi; Kenneth Tan; Arvind Sehgal
Journal:  Eur J Pediatr       Date:  2013-12-03       Impact factor: 3.183

Review 7.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

Review 8.  Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis.

Authors:  Matthias Lange; Christian Ertmer; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

Review 9.  Bench-to-bedside review: Vasopressin in the management of septic shock.

Authors:  James A Russell
Journal:  Crit Care       Date:  2011-08-11       Impact factor: 9.097

10.  Vasopressin improves outcome in out-of-hospital cardiopulmonary resuscitation of ventricular fibrillation and pulseless ventricular tachycardia: a observational cohort study.

Authors:  Stefek Grmec; Stefan Mally
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.